Navegar por autor "Reboredo Lopez, Margarita"

A phase II study of capecitabine in combination with erlotinib as first-line therapy in patients with metastatic pancreatic cancer (stage IV)

2011- Reboredo Lopez, Margarita; Candamio Folgar, Sonia; López López, Rafael; Quintero Aldana, Guillermo; Salgado Fernández, Mercedes; [et al.]

Circulating levels of GDF15, MMP7 and miR-200c as a poor prognostic signature in gastric cancer

2014- Valladares Ayerbes, Manuel; Haz Conde, María del Mar; Blanco Calvo, Moisés; Antón Aparicio, Luis Miguel; Reboredo Lopez, Margarita; [et al.]

Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer

2012- Valladares Ayerbes, Manuel; Reboredo Lopez, Margarita; Medina Villaamil, Vanessa; Iglesias Díaz, Pilar; Lorenzo Patiño, María José; [et al.]

Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen

2019- Martinez Lago, Nieves Purificacion; Carmona Campos, Marta; Gonzalez Villarroel, P; Salgado Fernández, Mercedes; De La Cámara Gómez, Juan Cruz; [et al.]

Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers

2019- Fernández Montes, Ana; Martinez Lago, Nieves Purificacion; Covela Rúa, Marta; De La Cámara Gómez, Juan Cruz; González Villaroel, Paula; [et al.]

Evaluation of the Adenocarcinoma-Associated Gene AGR2 and the Intestinal Stem Cell Marker LGR5 as Biomarkers in Colorectal Cancer

2012- Valladares Ayerbes, Manuel; Blanco Calvo, Moisés; Reboredo Lopez, Margarita; Lorenzo Patiño, María José; Iglesias Díaz, Pilar; [et al.]

First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours

2015- Reboredo Lopez, Margarita

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

2019- Carrato, A; Benavides, M; Massuti, B; Ferreiro-Monteagudo, R; Garcia Alfonso, P; [et al.]

Gemcitabine and Capecitabine as Third- or Later-line Therapy for Refractory Advanced Colorectal Cancer: A Retrospective Study

2013- Valladares Ayerbes, Manuel; Reboredo Lopez, Margarita; Fernández Montes, Ana; Varela Ferreiro, Silvia; Quintero Aldana, Guillermo; [et al.]

Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen

2012- Reboredo Lopez, Margarita; López López, Rafael

MicroRNA profile and KRAS status in metastatic colorectal cancer

2011- Valladares Ayerbes, Manuel; Haz Conde, María del Mar; Blanco Calvo, Moisés; Antón Aparicio, Luis Miguel; Reboredo Lopez, Margarita; [et al.]

MicroRNAs as emerging biomarkers for micrometastasis detection in genitourinary tumors

2011- Valladares Ayerbes, Manuel; Antolín Novoa, Silvia; Antón Aparicio, Luis Miguel; Reboredo Lopez, Margarita; Aparicio Gallego, Guadalupe; [et al.]

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

2019- Rivera, F.; Romero, C.; Jimenez-Fonseca, P.; Izquierdo-Manuel, M.; Salud, A.; [et al.]

Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)

2013- Reboredo Lopez, Margarita; Candamio Folgar, Sonia; López López, Rafael; Quintero Aldana, Guillermo; Salgado Fernández, Mercedes; [et al.]

Phase II Trial of MiniDOX in

2011- Valladares Ayerbes, Manuel; Reboredo Lopez, Margarita

Preliminary safety results of regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive

2015- Reboredo Lopez, Margarita

Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer

2011- Valladares Ayerbes, Manuel; Haz Conde, María del Mar; Blanco Calvo, Moisés; Antón Aparicio, Luis Miguel; Reboredo Lopez, Margarita; [et al.]

Prognostic Value of the Combination of Circulating Tumor Cells Plus KRAS in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab

2013- Reboredo Lopez, Margarita

Role of KRas Status in Patients With Metastatic Colorectal Cancer Receiving First-line Chemotherapy Plus Bevacizumab - a TTD Spanish Group Cooperative Study

2011- Reboredo Lopez, Margarita

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

2012- Reboredo Lopez, Margarita; Constenla Figueiras, Manuel

Repositorio digital RUNA

Navegar por autor "Reboredo Lopez, Margarita"

A phase II study of capecitabine in combination with erlotinib as first-line therapy in patients with metastatic pancreatic cancer (stage IV) ﻿

Circulating levels of GDF15, MMP7 and miR-200c as a poor prognostic signature in gastric cancer ﻿

Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer ﻿

Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen ﻿

Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers ﻿

Evaluation of the Adenocarcinoma-Associated Gene AGR2 and the Intestinal Stem Cell Marker LGR5 as Biomarkers in Colorectal Cancer ﻿

First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours ﻿

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) ﻿

Gemcitabine and Capecitabine as Third- or Later-line Therapy for Refractory Advanced Colorectal Cancer: A Retrospective Study ﻿

Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen ﻿

MicroRNA profile and KRAS status in metastatic colorectal cancer ﻿

MicroRNAs as emerging biomarkers for micrometastasis detection in genitourinary tumors ﻿

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial ﻿

Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study) ﻿

Phase II Trial of MiniDOX in ﻿

Preliminary safety results of regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive ﻿

Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer ﻿

Prognostic Value of the Combination of Circulating Tumor Cells Plus KRAS in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab ﻿

Role of KRas Status in Patients With Metastatic Colorectal Cancer Receiving First-line Chemotherapy Plus Bevacizumab - a TTD Spanish Group Cooperative Study ﻿

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study ﻿

A phase II study of capecitabine in combination with erlotinib as first-line therapy in patients with metastatic pancreatic cancer (stage IV)

Circulating levels of GDF15, MMP7 and miR-200c as a poor prognostic signature in gastric cancer

Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer

Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen

Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers

Evaluation of the Adenocarcinoma-Associated Gene AGR2 and the Intestinal Stem Cell Marker LGR5 as Biomarkers in Colorectal Cancer

First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Gemcitabine and Capecitabine as Third- or Later-line Therapy for Refractory Advanced Colorectal Cancer: A Retrospective Study

Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen

MicroRNA profile and KRAS status in metastatic colorectal cancer

MicroRNAs as emerging biomarkers for micrometastasis detection in genitourinary tumors

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)

Phase II Trial of MiniDOX in

Preliminary safety results of regorafenib (REG) as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients (pts) with metastatic colorectal cancer (mCRC): A phase II study of the Spanish Cooperative Group for Digestive

Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer

Prognostic Value of the Combination of Circulating Tumor Cells Plus KRAS in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab

Role of KRas Status in Patients With Metastatic Colorectal Cancer Receiving First-line Chemotherapy Plus Bevacizumab - a TTD Spanish Group Cooperative Study

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study